Madrigal Pharmaceuticals, Inc. MDGL NASDAQ

Madrigal Pharmaceuticals, Inc. (MDGL) generated $-189.55M in operating cash flow for fiscal year 2025. After capital expenditures of $467K, free cash flow was $-190.02M.

Free cash flow margin was -19.8% of revenue. Cash conversion ratio was 0.66x, suggesting some earnings are non-cash.

Criteria supported by this page:

• HEALTH (50/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
• MOAT (67/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
• INCOME (10/100) — Cash conversion ratio was 0.66x suggests some earnings are non-cash items

Overall SharesGrow Score: 54/100 with 2/7 criteria passed.